摘要
以多聚磷酸钠（TPP）为交联剂，采用乳化交联法制备了牛血清白蛋白（BSA）壳聚糖控释微球（CMs）。将微球与纳米羟基磷灰石／胶原（nHAC）、聚乳酸（PLA）按不同比例混合，采用热致分相法制备了CMs／nHAC／PLA复合支架材料。利用扫描电镜、激光粒度分析仪、压汞仪和力学性能测试仪考察了微球与复合支架的性能。结果表明：所制备的壳聚糖微球形态良好，呈规则球形，粒径主要分布在20-50μm；随BSA初始用量的增加，微球的载药量从0．78％增大到2．74％，但包封率从86．9％下降到78．4％；控制CMs用量不超过PLA质量的30％，则可保证微球在CMs／nHAC／PLA中的均匀分布，此时复合材料的孔径主要分布在100-200μm，孔隙率不低于83．1％，压缩强度在1-2MPa。这种复合支架材料可望作为人体非承重部位的植入骨修复体和组织工程支架使用。
Chitosan microspheres （CMs） loaded with bovine serum albumin （BSA） were prepared by an emulsionionic crosslinking method in the presence of tripolyphosphate （TPP）. Porous CMs/nano-hydroxyapatite/collagen/ polylactide （CMs/nHAC/PLA） composite was developed by thermally induced phase separation. The properties of the CMs and composite were investigated by SEM, laser particle size analyzer, mercury porosimeter and universal testing machine. The results indicate that the CMs are spherical in shape, with a regular surface. The diameters of the CMs are in the range of 20 - 50 μm. With the increase of initial BSA dosage, the loading capacity is also increased from 0. 78% to 2. 74%, whereas the encapsulation efficiency is decreased from 86. 9% to 78. 4%. Controlling the CMs dosage to be not higher than 30 % on a PLA weight basis, the CMs can distribute perfectly in the whole CMs/nHAC/PLA composite. The total porosity of the porous composite is over 83. 1%. The pore diameter is about 100- 200 μm, and the compressive strength is about 1 - 2 MPa. This porous composite is a promising material for non-loaded bone implants and tissue engineering scaffolds.
出处
《复合材料学报》
EI
CAS
CSCD
北大核心
2009年第2期143-148,共6页
Acta Materiae Compositae Sinica
基金
国家科技支撑计划基金(2006BAI16B02)
中国博士后科学基金(20070420330)
